



THOMSON MEDICAL GROUP LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 199908381D)

UPSIZING OF THE 5.25% NOTES DUE 2027 TO BE ISSUED PURSUANT TO THE S\$1,000,000,000 MULTICURRENCY DEBT ISSUANCE PROGRAMME OF THOMSON MEDICAL GROUP LIMITED FROM S\$140,000,000 TO S\$155,000,000 IN AGGREGATE PRINCIPAL AMOUNT

Reference is made to the announcement made by Thomson Medical Group Limited (the "**Issuer**") via SGXNet on 6 May 2024 (the "**Pricing Announcement**") in relation to the pricing of S\$140,000,000 in aggregate principal amount of 5.25% notes due 2027 (the "**Initial Notes**") to be issued pursuant to the S\$1,000,000,000 Multicurrency Debt Issuance Programme established by the Issuer on 28 June 2019 and updated on 21 April 2023 (the "**Programme**").

The Board of Directors of the Issuer wishes to announce that it will be issuing an additional S\$15,000,000 in aggregate principal amount of 5.25% fixed rate notes due 2027 (the "**Upsize Notes**").

For the avoidance of doubt, the Upsize Notes and the Initial Notes are to be issued on the same date and are comprised in the same series (the "**Series 004 Notes**").

Accordingly, the total issue size of the Series 004 Notes is now expected to be S\$155,000,000 (consisting of S\$140,000,000 in aggregate principal amount of Initial Notes and S\$15,000,000 in aggregate principal amount of Upsize Notes).

DBS Bank Ltd. has been appointed as the sole global coordinator and DBS Bank Ltd., Maybank Securities Pte. Ltd., Oversea-Chinese Banking Corporation Limited, UBS AG Singapore Branch, United Overseas Bank Limited have been appointed as the joint lead managers and joint bookrunners in relation to the Initial Notes and the Upsize Notes.

For the avoidance of doubt, other than the increase in issue size of the Series 004 Notes (pursuant to the expected issuance of the Upsize Notes), all other terms and conditions of the Series 004 Notes shall remain unchanged as set out in the Pricing Announcement.

The Series 004 Notes will not be sold or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor (as defined in Section 4A of the Securities and Futures Act 2001 of Singapore (the "**SFA**")) pursuant to Section 274 of the SFA, or (ii) to an accredited investor (as defined in Section 4A of the SFA) pursuant to and in accordance with the conditions specified in Section 275 of the SFA and (where applicable) Regulation 3 of the Securities and Futures (Classes of Investors) Regulations 2018.

Application will be made to the SGX-ST for the listing and quotation of the Series 004 Notes on the SGX-ST. Such permission will be granted when the Series 004 Notes have been admitted to the Official List of the SGX-ST. The SGX-ST assumes no responsibility for the correctness of any of the statements made, opinions expressed or reports contained herein. Approval in-principle from, admission to the Official List of, and the listing and quotation of the Series 004 Notes on, the SGX-ST are not to be taken as an indication of the merits of the Issuer, its subsidiaries, its associated companies (if any), the Programme or the Series 004 Notes.

By Order of the Board

Wilson Sam

Executive Director and Group Chief Financial Officer

7 May 2024